# VITAMIN E ACTIVITY OF 1-THIO-α-TOCOPHEROL AS MEASURED BY THE RAT CURATIVE MYOPATHY BIOASSAY

## K.U. INGOLD<sup>1†</sup>, G.W. BURTON<sup>1</sup>, L. HUGHES<sup>1</sup>, D.O. FOSTER<sup>2</sup> and B. ROBILLARD<sup>1‡</sup>

Divisions of Chemistry<sup>1</sup> and Biological Sciences<sup>2</sup>, National Research Council of Canada, 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6

(Received May 9, 1990; in revised form June 26, 1990)

The bioactivity of the acetate of the all-racemic, 1-thio analog of  $\alpha$ -tocopherol (*all-rac*-1-thio- $\alpha$ -tocopheryl acetate) has been determined by measuring its ability to decrease plasma levels of pyruvate kinase in vitamin E deficient rats using the curative myopathy bioassay. The thio analog is only 0.22 times as active as *RRR*- $\alpha$ -tocopheryl acetate and is therefore approximately 0.33 times as active as *all-rac*- $\alpha$ -tocopheryl acetate, since the latter has been shown to be 1.47 times less active than *RRR*- $\alpha$ -tocopheryl acetate in the same bioassay (H. Weiser, M. Vecchi and M. Schlachter, *Internat. J. Vit. Nutr. Res.*, **55**, 149–158 (1985)). The 0.33:1.0 ratio is similar to the ratio of 0.41:1.0 measured for the *in vitro* antioxidant activities of the corresponding free phenols. This finding lends further support to our view that the vitamin E activity in the curative myopathy bioassay of close structural analogs of  $\alpha$ -tocopherol is determined primarily by the *in vitro* antioxidant activity of the analog relative to  $\alpha$ -tocopherol. consistent with the belief that vitamin E functions primarily as a general purpose, lipid-soluble antioxidant in mammals.

KEY WORDS: Vitamin E, antioxidant, 1-thio-α-tocopherol, pyruvate kinase, curative myopathy assay.

#### INTRODUCTION

In a number of publications we have made use of the rat curative myopathy bioassay to determine the vitamin E activity of some analogs of  $\alpha$ -tocopherol,  $\alpha$ -T.<sup>1-3</sup> We discovered that a dihydrobenzofuran analog (with one less CH<sub>2</sub> group in the heterocyclic ring) is more active than  $\alpha$ -T<sup>1.2</sup> and that analogs having a non-branched, saturated hydrocarbon "tail" with 11 or 13 carbon atoms are about as active as  $\alpha$ -T.<sup>3</sup> We have taken these results as providing strong supporting evidence for the prevailing view<sup>3.4</sup> that  $\alpha$ -T and related phenols (ArOH) owe their biological activity simply and entirely to their ability to inhibit lipid peroxidation via reaction 1. This conclusion would be

$$ROO \cdot + ArOH \xrightarrow{\wedge_1} ROOH + ArO \cdot$$
 (1)


further strengthened if it could be demonstrated that vitamin E activity was retained in  $\alpha$ -T analogs in which the oxygen at the 1-position had been replaced by a different heteroatom. The need to maintain a reasonably good antioxidant activity in such an  $\alpha$ -T analog (i.e. a  $k_1$  value not too much smaller than that found for  $\alpha$ -T)<sup>5-8</sup> requires that the new heteroatom have, like oxygen, a *p*-type lone pair of electrons. This will

<sup>†</sup>Author to whom correspondence should be addressed. Tel: 613-990-0938, Fax: 613-952-0974.


<sup>‡</sup>Present address: 4 rue Jean Sebastien Bach, 52100 Epernay, France.

#### K.U. INGOLD ET AL.

allow the unpaired electron in the ArO· radical to be delocalized onto the heteroatom which provides thermodynamic stabilization to the radical and hence an acceptably high  $k_1$  value.<sup>5-8</sup> The logical replacement heteroatom is sulfur, particularly since sulfur is generally considered to be more effective than oxygen at stabilizing a neighbouring radical center.<sup>9-13</sup> With this in mind we synthesized 2RS, 4'RS, 8'RS-1-thio- $\alpha$ -tocopherol, *all-rac*-1.<sup>14,15</sup>



2R,4'R,8'R-\alpha-tocopherol (natural vitamin E), RRR-\alpha-T



2RS,4'RS,8'RS-1-thio-α-tocopherol, all-rac-1

An *in vitro* study of the antioxidant activity of *all-rac*-1 was disappointing in that this compound was found to be a less effective antioxidant than  $\alpha$ -T.<sup>15</sup> The stoichiometric factor, *n* (i.e., the number of peroxyl radicals trapped per molecule of ArOH), was between 1.0 and 1.8 for 1 whereas it is 2.0 for  $\alpha$ -T.<sup>15</sup> Furthermore, the rate constant,  $k_1$ , for trapping of the initial peroxyl radical was smaller for 1 than for  $\alpha$ -T. The effective antioxidant activity of an ArOH is determined by the product of these two quantities, i.e., by  $nk_1$ . For 1,  $nk_1 = 2.6 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$  and for  $\alpha$ -T,  $nk_1 = 6.4 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ .<sup>15</sup> Thus, 1 is only ca. 40% as active an antioxidant as  $\alpha$ -T. Despite this disappointing result we decided to check the vitamin E activity of *all-rac*-1 using the rat curative myopathy bioassay.<sup>1-3,16</sup>

#### MATERIALS AND METHODS

All-rac-1 was synthesized as described previously,<sup>14,15</sup> and was converted to the acetate for bioassaying. The rat curative myopathy bioassay, which is based on the decrease of the highly elevated pyruvate kinase (PK) activities of vitamin E-deficient rats, was conducted essentially as described previously.<sup>1-3,16</sup> In brief, male weanling (21–22 days old) Sprague Dawley rats were provided with tap water and a vitamin E-free diet *ad libitum*. The diet was based on the AIN 76 formulation<sup>17</sup> but contained 10% tocopherol-stripped corn oil (with 0.02% BHT), a menadione concentration of 500  $\mu$ g/kg diet, sucrose decreased to 20%, the starch increased to 30% and 10% dyetrose (a selectively depolymerized corn starch, which permitted the diet to be pelleted). This diet, which was obtained from Dyets Inc., Bethlehem, PA, was fed for 16 weeks prior to use of the animals in the vitamin E bioassay.

Two bioassays were performed. Each bioassay normally employed 36 rats, each receiving one of three doses of either *all-rac*-1 or *RRR-α*-T as their acetates (i.e., 18 rats per compound and 6 per dose level) daily for 4 days. On day 1, before dosing, and on day 5 (23–24 h after the last dose) blood (0.5–1.0 mL) was obtained by cardiac puncture under brief halothane anesthesia (5% in  $O_2$ , 1–2 min), mixed with Na<sub>2</sub>ED-TA (1 mg/mL), chilled on ice and centrifuged at 8,000 × g for 1 min to sediment cells. The plasma was retained and stored on ice until assayed (within 1 to 1.5 h) for PK activity, essentially as described by Gutman and Bernt.<sup>18</sup> The rats were ranked in order of initial (day 1) plasma PK and divided sequentially into 6 groups. The 6 rats in each group were than randomly assigned to receive one of the three doses of either test compound. The test compounds were dissolved in tocopherol-stripped corn oil and administered *per os* (250  $\mu$ L/kg body weight) with a positive displacement pipette. After blood sampling on day 5 the animals were killed by exposure to gaseous CO<sub>2</sub>.

For each bioassay the linear regression of plasma PK activity (units/mL) vs ln (dose) of test compound was computed by the method of least squares and, provided that parallelism of the dose response lines was not statistically rejected by analysis of variance, a common slope was calculated and applied to the regressions. The ratio of potencies of *all-rac*-1 acetate and *RRR-\alpha*-T acetate was computed from the horizontal displacement of the two lines.

### **RESULTS AND DISCUSSION**

Two separate bioassay experiments were conducted. They yielded potency ratios for *all-rac*-1 acetate to *RRR*- $\alpha$ -T acetate equal to 0.23:1.0 and 0.22:1.0, respectively (both




FIGURE 1 Dose-dependence of the decrease in plasma pyruvate kinase (PK) levels measured on day 5 in vitamin E deficient rats after administration of either RRR- $\alpha$ -T-Ac (O) or all-rac-1-Ac ( $\Delta$ ) given once per day for four consecutive days. Each data point is the mean of data from six animals. The potency ratio for all-rac-1 acetate to RRR- $\alpha$ -T acetate in this experiment was 0.23:1.0 (p < 0.01). A duplicate experiment gave a ratio of 0.22:1.0 (p < 0.01). The baseline PK level in vitamin E-sufficient rats is about 0.2 units mL<sup>-1</sup>.<sup>1</sup>



with p < 0.01). The results of one of the bioassays are shown in Figure 1. Because of the greater bioactivity of the 2*R* stereoisomer relative to the 2*S* stereoisomer of  $\alpha$ -T<sup>16,19-25</sup> and the dihydrobenzofuran analog<sup>2</sup> it is probably more appropriate to compare the activity of *all-rac*-1-acetate with that of *all-rac*- $\alpha$ -T acetate. This is easily done since Weiser *et al.*<sup>26</sup> have employed the rat curative myopathy bioassay to measure the potency ratio for *RRR*- $\alpha$ -T acetate vs. *all-rac*- $\alpha$ -T acetate: *RRR*- $\alpha$ -T acetate potency ratio of 1.47:1.0. Multiplying the mean *all-rac*-1 acetate: *RRR*- $\alpha$ -T acetate potency ratio of 0.22:1.0 by 1.47 yields the potency ratio for *all-rac*-1-acetate:all-rac- $\alpha$ -T acetate, viz. 0.33:1.0. This potency ratio is in good agreement with the ratio of the *in vitro* antioxidant activities of 1: $\alpha$ -T, *viz.*,<sup>15</sup> 0.40:1.0. This result lends further support to our view,<sup>1-3</sup> that the vitamin E activity (as measured by the rat curative myopathy bioassay) of close structural analogs of  $\alpha$ -T is determined primarily by the antioxidant activity of the analog relative to  $\alpha$ -T.

#### **Acknowledgements**

We thank Mrs. H. Burton for help with the animals, Mrs. S. Lacelle for help with the bioassay, Dr. M. Zuker for designing the statistical analysis program and Mrs. L. Bramall for performing the statistical analyses. We also thank the Association for International Cancer Research, the National Foundation for Cancer Research, Eastman Chemicals Products, Inc., Eisai Co., Ltd., Henkel Corporation and Sterling Drug, Inc., for support of this work.

#### References

- K.U. Ingold, G.W. Burton, D.O. Foster, M. Zuker, L. Hughes, S. Lacelle, E. Lusztyk and M. Slaby (1986) A new vitamin E analogue more active than α-tocopherol in the rat curative myopathy bioassay. *FEBS Letters*, **205**, 117-120.
- 2. K.U. Ingold, G.W. Burton, D.O. Foster and L. Hughes (in press) Further studies of a new vitamin E analogue more active than  $\alpha$ -tocopherol in the rat curative myopathy bioassay. *FEBS Letters*.
- K.U. Ingold, G.W. Burton, D.O. Foster and L. Hughes (in press) Is methyl-branching in α-tocopherol's "tail" important for its *in vivo* activity? Rat curative myopathy bioassay measurements of the vitamin E activity of three 2RS-n-alkyl-2,5,7,8-tetramethyl-6-hydroxychromans. Free Radical Biology Medicine.
- 4. L.J. Machlin, ed., (1980) Vitamin E: A Comprehensive Treatise. Dekker: New York, N.Y.
- G.W. Burton, Y. Le Page, E.J. Gabe and K.U. Ingold (1980) The antioxidant activity of vitamin E and related phenols. The importance of stereoelectronic factors. *Journal of the American Chemical Society*, 102, 7791-7792.
- G.W. Burton and K.U. Ingold (1981) Autoxidation of biological molecules. I. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. Journal of the American Chemical Society, 103, 6472-6477.
- G.W. Burton, L. Hughes and K.U. Ingold (1983) Antioxidant activity of phenols related to vitamin E. Are there chain-breaking antioxidants better than a-tocopherol? *Journal of the American Chemical* Society, 105, 5950-5951.
- G.W. Burton, T. Doba, E.J. Gabe, L. Hughes, F.L. Lee, L. Prasad and K.U. Ingold (1985) Autoxidation of biological molecules. 4. Maximizing the antioxidant activity of phenols. *Journal of the American Chemical Society*, 107, 7053-7065.
- 9. I. Biddles, A. Hudson and J.T. Whiffen (1972) A comparative study of some oxygen and sulphur substituted alkyl radicals. *Tetrahedron*, 28, 867-874.
- 10. D.D.M. Wayner and D.R. Arnold (1984) Substituent effects on benzyl radical hyperfine coupling constants. Part 2. The effect of sulfur substitutents. Canadian Journal of Chemistry, 62, 1164-1168.
- D.C. Nonhebel and J.C. Walton (1984) Estimation of bond dissociation energies, including DH<sup>0</sup> (RSCH<sub>2</sub>-H), from barriers to internal rotation. Journal of the Chemical Society, Chemical Communications, 731-732.

RIGHTSLINKA)

- 12. D. Griller, D.C. Nonhebel and J.C. Walton (1984) An electron spin resonance study of 1-alkylthioallyl, 3-alkylthiopropynyl, and alkylthioalkyl radicals: an examination of spin delocalization by alkylthio groups. *Journal of the Chemical Society, Perkin Transactions*, **2**, 1817–1821.
- 13. A.E. Luedtke and J.W. Timberlake (1985) Effect of oxidized states of heteroatoms and of orthogonal  $\pi$  systems on radical stabilities. *Journal of Organic Chemistry*, **50**, 268-270.
- 14. B. Robillard and K.U. Ingold (1986) Total synthesis of 1-thio-α-tocopherol: a sulfur-containing analogue of vitamin E. *Tetrahedron Letters*, 27, 2817–2820.
- H.A. Zahalka, B. Robillard, L. Hughes, J. Lusztyk, G.W. Burton, E.G. Janzen, Y. Kotoke and K.U. Ingold (1988) Antioxidant activity of 1-thio-α-tocopherol and related compounds. EPR, ENDOR and UV-visible absorption spectra of some of the derived phenoxyl radicals. *Journal of Organic Chemistry*, 53, 3739–3745.
- 16. H. Weiser, M. Vecchi and M. Schlachter (1986) Stereoisomers of  $\alpha$ -tocopheryl acetate. IV. Units and  $\alpha$ -tocopherol equivalents of *all-rac-, 2-ambo-,* and *RRR-\alpha*-tocopherol evaluated by simultaneous determination of resorption-gestation, myopathy, and liver storage capacity in rats. *International Journal of Vitamin and Nutrition Research*, **56**, 45-56.
- 17. J.G. Bieri (1980) Second report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. *Journal of Nutrition*, **110**, 1726.
- I. Gutman and E. Bernt (1974) Pyruvate kinase. Assay in serum and erythrocytes. In Methods of Enzymatic Analysis, H.U. Bergmeyer, ed., Vol. 2, 2nd ed., Academic Press: New York, N.Y., pp 774-778.
- S.R. Ames, M.I. Ludwig, D.R. Nolan and C.D. Robeson (1963) Biological activity of an *l*-epimer of *d*-α-tocopheryl acetate. *Biochemistry*, 2, 188-190.
- M.L. Scott and I.D. Desai (1964) The relative antimuscular dystrophy activity of the d- and l-epimers of α-tocopherol and of other tocopherols in the chick. Journal of Nutrition, 83, 39-43.
- L.A. Witting, M.K. Horwitt (1964) Biopotency of l-α-tocopherol acetate for the rat. Proceedings of the Society of Experimental Biology and Medicine, 116, 655-658.
- 22. S.R. Ames (1971) Isomers of  $\alpha$ -tocopheryl acetate and their biological activity. Lipids, 6, 281-290.
- S.R. Ames (1979) Biopotencies in rats of several forms of alpha-tocopherol. Journal of Nutrition, 109, 2198-2204.
- H. Weiser and M. Vecchi (1981) Stereoisomers of α-tocopheryl acetate. Characterization of the samples by physico-chemical methods and determination of biological activities in the rat resorptiongestation test. International Journal of Vitamin and Nutrition Research, 51, 100-113.
- H. Weiser and M. Vecchi (1982) Stereoisomers of α-tocopheryl acetate. II. Biopotencies of all eight stereoisomers, individually or in mixtures, as determined by rat resorption-gestation tests. *Internation*al Journal of Vitamin and Nutrition Research, 52, 351-370.
- 26. H. Weiser, M. Vecchi and M. Schlachter (1985) Stereoisomers of  $\alpha$ -tocopheryl acetate. III. Simultaneous determination of resorption-gestation and myopathy in rats as a means of evaluating biopotency ratios of *all-rac-* and *RRR*-a-tocopheryl acetate. *International Journal of Vitamin and Nutrition Research*, **55**, 149-158.

Accepted by Prof. H. Sies

RIGHTSLINKA)